Professor Anna Schuh’s main laboratory research interest is with the development, evaluation and implementation of new technologies for Precision Diagnostics. Her research group published the first longitudinal study of the changes in the genomic landscape of patients undergoing treatment for leukemia and led pivotal studies in collaboration with Genomics England. She has a strong focus on liquid biopsies in early cancer detection. Her group published the first deep whole genome analysis of circulating tumour DNA, and she has research programmes in this area in the UK, Uganda and Tanzania. She also spearheaded the creation of an online and part-time Oxford Master’s Programme in Precision Cancer Medicine.

Professor Schuh completed academic and clinical hematology training in Oxford. She acted as the director of the NHS Haematology Laboratories including molecular diagnostics from 2006 to 2014. Over the past 15 years, she has led over 50 early and late phase clinical trials in chronic lymphocytic leukemia as a principal or chief investigator. A number of these have changed clinical practice for patients in the UK and worldwide. She served as chair of the UK CLL forum from 2015 to 2018, was appointed Chair of the National Cancer Research Institute Collaborative Group for Chronic Lymphocytic Leukaemia in 2018, and to the board of the iwCLL in 2019.

Professor Schuh has authored or co-authored over 150 peer-reviewed publications. She holds a patent in non-invasive prenatal diagnosis, has been a co-founder of two biotechnology start-ups and of Seren, a social enterprise to improve access to DNA-based diagnostics in sub-Saharan Africa.